{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cognition+in+Schizophrenia&page=2",
    "query": {
      "condition": "Cognition in Schizophrenia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cognition+in+Schizophrenia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T04:58:53.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04846868",
      "title": "Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Iclepertin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 620,
      "start_date": "2021-09-08",
      "completion_date": "2024-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 18,
      "location_summary": "Garden Grove, California • La Habra, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "La Habra",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04846868"
    },
    {
      "nct_id": "NCT00931996",
      "title": "Oculomotor and Spatial Cognition Deficits in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Antipsychotic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "15 Years to 64 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931996"
    },
    {
      "nct_id": "NCT01696929",
      "title": "An Open-Label Trial of Tocilizumab in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brian Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 8,
      "start_date": "2012-09",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-29",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696929"
    },
    {
      "nct_id": "NCT01292577",
      "title": "Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "CET/PT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as Usual",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 33,
      "start_date": "2010-09",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2020-04-13",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01292577"
    },
    {
      "nct_id": "NCT07263022",
      "title": "Cognitive Strategies in Early Psychosis 2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psychosis",
        "Schizophrenia Disorder",
        "Schizoaffective Disorder",
        "Major Depressive Disorder With Psychotic Features",
        "Bipolar Disorder With Psychotic Features",
        "Psychosis NOS",
        "Schizophreniform Disorder",
        "Psychotic Disorder",
        "Cognition"
      ],
      "interventions": [
        {
          "name": "Modafinil",
          "type": "DRUG"
        },
        {
          "name": "D-serine solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-07-17",
      "completion_date": "2030-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07263022"
    },
    {
      "nct_id": "NCT00383747",
      "title": "The Effects of Nicotine on Cognition in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Transdermal Nicotine Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2004-04",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383747"
    },
    {
      "nct_id": "NCT02237235",
      "title": "Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "MMFS-202-302",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-08",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237235"
    },
    {
      "nct_id": "NCT00492336",
      "title": "Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "rasagiline (Pharmacodynamics)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 84,
      "start_date": "2007-01",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Catonsville",
          "state": "Maryland"
        },
        {
          "city": "Catonsville",
          "state": "Maryland"
        },
        {
          "city": "Catonsville",
          "state": "Maryland"
        },
        {
          "city": "Dundalk",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492336"
    },
    {
      "nct_id": "NCT00601224",
      "title": "Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Social cognition and interaction training (SCIT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as usual (TAU)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2007-06",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-03-29",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00601224"
    },
    {
      "nct_id": "NCT00963846",
      "title": "Huperzine for Cognitive and Functional Impairment in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "huperzine 0.2 mg BID",
          "type": "DRUG"
        },
        {
          "name": "huperzine 0.4 mg BID",
          "type": "DRUG"
        },
        {
          "name": "huperzine 0.8 mg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomedisyn Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-01",
      "last_synced_at": "2026-07-24T04:58:53.562Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963846"
    }
  ]
}